Dr. Joseph on Factors Influencing Frontline Therapy Selection in mRCC

Richard W. Joseph, MD
Published: Monday, Aug 05, 2019



Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses considerations for frontline therapy selection for patients with metastatic renal cell carcinoma (mRCC).

The first thing that needs to be to be taken into consideration is a patient’s risk status, whether it’s good, intermediate, or poor. Risk status was initially designed to be prognostic, but can also be used to predict biology, adds Joseph.

In addition to risk status, a patient’s comorbidities should also be used to guide therapy selection. For example, if a patient has a cardiac history, is anti-VEGF therapy the best choice? Additionally, any soft or hard contraindication to immunotherapy could help eliminate an immunotherapy-based therapy from the equation. Ultimately, the decision comes down to good clinical judgement, concludes Joseph.
SELECTED
LANGUAGE


Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses considerations for frontline therapy selection for patients with metastatic renal cell carcinoma (mRCC).

The first thing that needs to be to be taken into consideration is a patient’s risk status, whether it’s good, intermediate, or poor. Risk status was initially designed to be prognostic, but can also be used to predict biology, adds Joseph.

In addition to risk status, a patient’s comorbidities should also be used to guide therapy selection. For example, if a patient has a cardiac history, is anti-VEGF therapy the best choice? Additionally, any soft or hard contraindication to immunotherapy could help eliminate an immunotherapy-based therapy from the equation. Ultimately, the decision comes down to good clinical judgement, concludes Joseph.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x